CujpersP, et al.: Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: A meta-analysis. Depress Anxiety, 2009; 26:279–288.
2.
AnttilaSA, et al.: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev, 2001; 7:249–264.
3.
CroomK, et al.: Mirtazapine: A review of its use in major depression and other psychiatric disorders. CNS Drugs, 2009; 23:427–452.
4.
TábiT, et al.: The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease. Expert Opin Drug Metabol Toxicol, 2013; 9:5, 629–636.
5.
LeeKC, et al.: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat, 2007; 3:527–537.
6.
KaminskyB, et al.: Alternative routes of administration of antidepressant and antipsychotic medications. Ann Pharmacother, 2015; 49:808–817.
7.
AttardA, et al.: Alternative routes to oral antidepressant therapy: Case vignette and literature review. J Psychopharmacol, 2010; 24:449–454.
8.
KoelleJ, et al.: Antidepressants for the viscerally eviscerated patient: Options instead of oral dosing. Psychosom Med, 1998; 60:723–725.
9.
AzranC, et al.: Impaired oral absorption of methylphenidate after Roux-en-Y gastric bypass. Surg Obes Relat Dis, 2017; 13:1245–1247.
McGirrA, et al.: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med, 2015; 45:693–704.
12.
ZarateCA, et al.: Ketamine for depression: Evidence, challenges and promise. World Psychiatry, 2015; 14:348–350.
13.
CoyleC, et al.: The use of ketamine as an antidepressant: A systematic review and meta-analysis. Hum Psychopharmacol Clin Exp, 2015; 30:152–163.
14.
SanacoraG, et al.: A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry, 2017; 74:399–405.
